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GI symptoms as early signs of 
COVID-19 in hospitalised 
Italian patients
In their recent publication in Gut, Lin et 
al report 11% of patients infected with 
SARS- CoV-2 (COVID-19) to present 
at admission with GI symptoms1; early 
observations reported that COVID-19 
could present with GI symptoms in 3% 
of patients.2 3 Diarrhoea, nausea, vomiting 
and/or abdominal pain or discomfort have 
been described at disease onset or even 
before respiratory symptoms.4–7
We investigated all consecutive indi-
viduals suspected to harbour COVID-19 
and admitted at the General Hospital 
of Crema between 21 February and 13 
March 2020 to assess prevalence and 
features of GI symptoms in COVID-19 
patients and their correlation with medical 
history, disease course and outcome.
All suspected individuals admitted to the 
hospital underwent a standardised work- 
up. Based on clinical, laboratory and radio-
logical findings, patients were discharged to 
quarantine or hospitalised. Demographic 
data, date of onset and type of symptoms 
at admission, including GI symptoms (as 
either nausea, or vomiting or diarrhoea or 
abdominal pain), and hospitalisation data 
were recorded. Primary outcomes were: 
need of continuous positive airway pressure 
(CPAP) or non- invasive ventilation (NIV), 
intensive care unit (ICU) admission and 
death.
Among 411 consecutive COVID-19 
patients (with positive RT- PCR), 42 
(10.2%, 15 females and 27 males, mean 
age 68.2±14.2) reported GI symptoms 
including nausea (18, 4.3%), vomiting (16, 
3.8%), diarrhoea (15, 3.6%) or abdom-
inal pain (5, 1.2%). GI symptoms had a 
mean onset of 4.9±4.4 days (range 1–20) 
before admission. Absence of cough was 
reported in 35/42 (83%) patients with GI 
symptoms compared with 225/369 (61%) 
patients without GI symptoms (p=0.004), 
with 15% vs 13% of them, respectively, 
having negative chest imaging. The 
frequency of fever was similar (p=0.7) 
in the two groups. In 5 of 411 patients 
(1.2%), GI symptoms were neither asso-
ciated with fever nor cough. GI symptoms 
did not show any significant correlation 
with syncope (p=0.3), use of ACE inhib-
itors (p=0.1), presence of comorbidities 
(p=0.3) or use of multiple drugs (p=0.7). 
Of the 42 patients presenting with GI 
symptoms, 9 (21.4%) required CPAP/
NIV, 1 (2.3%) was admitted to ICU and 
4 (9.5%) died. Table 1 shows correlation 
of GI symptoms with outcomes as either 
CPAP/NIV or ICU admission or death.
Our finding of 10% of patients confirms 
that the prevalence of GI symptoms at 
onset is not negligible.1 4
GI symptoms can herald COVID-19 as 
they presented on average 4.9 days before 
admission, with a very wide range with up to 
20 days before admission. Our data confirm 
the importance of including GI symp-
toms among the spectrum of COVID-19 
features, to allow early diagnosis and appro-
priate treatments even in patients without 
respiratory symptoms. This could be of 
particular importance considering the rapid 
human- to- human transmission among 
close contacts, which could be related to 
GI viral infection and potential oral- faecal 
transmission, possibly persisting even 
after viral clearance from the respiratory 
tract.5 6 8–10 In our cohort, GI symptoms 
did not correlate with fever, syncope, use of 
ACE inhibitors or multiple drugs, comor-
bidities. Conversely, we found a strong 
correlation with the absence of cough: we 
suggest that, as rate of lung involvement 
was similar in the two groups, patients with 
GI involvement might have a more silent 
lung involvement. Even if a possibly more 
benign disease course in patients with GI 
symptoms could be suggested by the trend 
of ICU admissions and deaths, which was 
lower compared with patients without GI 
symptoms at onset, the difference proved 
non- significant.
GI manifestations of COVID-19 are 
early, and possibly isolated, signs of the 
disease. Patient management and isolation 
policies should be accordingly tailored.
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PostScript
Table 1 Correlation of GI symptoms with 
CPAP/NIV, ICU admission or death
GI symptoms Non- GI symptoms P value
CPAP/NIV, n (%) 9 (21.4) 103 (27.9) 0.37
ICU, n (%) 1 (2.4) 27 (7.3) 0.23
Death, n (%) 4 (9.5) 68 (18.4) 0.15
CPAP, continuous positive airway pressure; ICU, intensive care unit; NIV, non- invasive 
ventilation.
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